Results showed that GSNO increased the percentage of iNOS+/MHC-II+ cells (%CD45+)(M1 macrophages), tumor-infiltrating lymphocytes (CD8+(%CD45+) cells), EM-CD8+ (CD44+CD62L−), MEM-CD8+ (CD44+ CD62L+), and naive CD8+ cells (%CD45+) and reduced the percentage of CD206+ (%CD45+)(M2 macrophages), F480+ (%CD45+)(macrophages), and CD11b+(%CD45+)(myeloid) cells (Fig. 5E). The gene discussed is CD44; the disease is neoplasm.